HealthCare Links
Healthcare News
- 2013-05-24 Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome
2013-05-24
Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome
Following an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year / Xarelto 2.5 mg BID in combination with antiplatelet therapy can help prevent athero-thrombotic events by providing more complete protection than antiplatelet therapy alone / Xarelto is approved to protect patients from blood clots across more venous and arterial thromboembolic conditions than any other novel oral anticoagulant more
- 2013-05-20 Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
2013-05-20
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) more
- 2013-05-17 Bayer European Regulatory update on Diane-35
2013-05-17
Bayer European Regulatory update on Diane-35
Bayer HealthCare Pharmaceuticals welcomes the statement of the Product Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) affirming the positive benefit-risk profile of Diane-35 provided that several measures are implemented to minimize the risk of thromboembolism. more
Photos & Videos
Bayer Healthcare
Bayer HealthCare Links
150 years of Bayer
Annual Report 2012
